John H. Stone
YOU?
Author Swipe
Burden of Metabolic Bone Disease in Patients with Immunoglobulin G4-Related Disease With and Without Autoimmune Pancreatitis: A Cross-Sectional Study Open
INTRODUCTION: Patients with immunoglobulin G4-related disease (IgG4-RD) have risk factors of metabolic bone disease (MBD), yet data are lacking on the prevalence of MBD in IgG4-RD. We assessed screening frequency and prevalence of MBD in p…
IgG4-related disease: lessons from the first 20 years Open
Immunoglobulin G4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory disease that is believed but not confirmed to have an autoimmune origin. Since its discovery nearly two decades ago, our understanding of its patho…
View article: Omics in IgG4-related disease
Omics in IgG4-related disease Open
Research on IgG4-related disease (IgG4-RD), an autoimmune condition recognized to be a unique disease entity only two decades ago, has processed from describing patients’ symptoms and signs to summarizing its critical pathological features…
View article: Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy
Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy Open
BACKGROUND: Patients with autoimmune blistering diseases (AIBDs) are often exposed to chronic glucocorticoid (GC) treatment with many side effects. Glucocorticoid-induced myopathy (GIM) is a well-established side effect, which particularly…
The role of statin therapy in older adults: best practices and unmet challenges Open
Guidelines for the use of statins for primary CVD prevention in older adults is conflicting. Collectively, evidence to date suggests statin therapy may be beneficial for primary CVD prevention in older adults free of life-limiting comorbid…
View article: Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy
Autoimmune blistering diseases treated with glucocorticoids: An international study of steroid‐induced myopathy Open
Background Patients with autoimmune blistering diseases (AIBDs) are often exposed to chronic glucocorticoid (GC) treatment with many side effects. Glucocorticoid‐induced myopathy (GIM) is a well‐established side effect, which particularly …
The clinical outcomes and healthcare resource utilization in IgG4-related disease: a claims-based analysis of commercially insured adults in the United States Open
Objectives IgG4-related disease (IgG4-RD) can affect nearly any organ and is often treated with glucocorticoids, which contribute to organ damage and toxicity. Comorbidities and healthcare utilization in IgG4-RD are poorly understood. Meth…
View article: Multimodality Imaging Features of Immunoglobulin G4–related Vessel Involvement
Multimodality Imaging Features of Immunoglobulin G4–related Vessel Involvement Open
Immunoglobulin 4 (IgG4)-related disease is a chronic immune-mediated fibroinflammatory disorder. Involvement of the vascular system, including large- and medium-sized vessels, is increasingly recognized. The varied appearances of vascular …
Longitudinal assessment of glucocorticoid toxicity in biologics treated severe asthma Open
Introduction: New biologics for severe eosinophilic asthma (SEA) significantly reduce oral corticosteroid (CS) exposure with the potential to reduce side effects from CS toxicity. We have previously reported CS toxicity using the glucocort…
View article: Treatment of IgG4-related disease-associated hypertrophic pachymeningitis with intrathecal rituximab: a case report
Treatment of IgG4-related disease-associated hypertrophic pachymeningitis with intrathecal rituximab: a case report Open
IgG4-related disease-associated hypertrophic pachymeningitis (IgG4RD-HP) is a fibroinflammatory autoimmune disorder in which diagnosis is difficult without biopsy. Guidance on management of disease refractory to glucocorticoids and intrave…
View article: Comparative Effectiveness of Rituximab‐ Versus <scp>Cyclophosphamide‐Based</scp> Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis for the Risk of Kidney Failure and Mortality
Comparative Effectiveness of Rituximab‐ Versus <span>Cyclophosphamide‐Based</span> Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis for the Risk of Kidney Failure and Mortality Open
Objective To compare rituximab‐ versus cyclophosphamide‐based remission induction strategies for the long‐term risks of kidney failure and death in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) in a real‐world coho…
Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis Open
Objective To assess outcomes in giant cell arteritis (GCA) patients during and after long-term tocilizumab (TCZ) treatment. Methods Retrospective analysis of GCA patients treated with TCZ at a single centre (2010–2022). Time to relapse and…
View article: Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism
Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism Open
Background The frequency of proteinase 3 gene (PRTN3) polymorphisms in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is not fully characterised. We hypothesise that the presence of a PRTN3 gene polymo…
Risk factors for serious infections in ANCA-associated vasculitis Open
OBJECTIVES: Severe infections contribute to morbidity and mortality in antineutrophil cytoplasm antibody-associated vasculitis (AAV). This study aimed to identify risk factors associated with severe infections in participants of the Rituxi…